Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 9

Results For "ADCs"

90 News Found

Merck KGaA to expand its membrane and filtration manufacturing facility in Ireland
News | May 23, 2022

Merck KGaA to expand its membrane and filtration manufacturing facility in Ireland

The company will invest approximately €440 million to increase membrane manufacturing capacity in Carrigtwohill and to build a new manufacturing facility at Blarney Business Park, both in Cork, Ireland


Biocytogen signs RenMab/RenLite licensing agreement with BeiGene
Biotech | April 26, 2022

Biocytogen signs RenMab/RenLite licensing agreement with BeiGene

In addition, common light chain antibodies generated by RenLite mice can greatly improve the efficiency of downstream assembly of complex drug molecules such as bispecific antibodies and bispecific antibody-drug conjugates (bsADCs)


Sanofi and Seagen to jointly develop multiple novel antibody-drug conjugates
Biotech | March 16, 2022

Sanofi and Seagen to jointly develop multiple novel antibody-drug conjugates

Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer


HCmed, Formosa Laboratories, and Formosa Pharmaceuticals form CDMO
Biotech | March 07, 2022

HCmed, Formosa Laboratories, and Formosa Pharmaceuticals form CDMO

According to statistics, the global inhalation drug market reached US $ 25 billion in 2020


Piramal Pharma Solutions plans expansion in Scotland
News | February 09, 2022

Piramal Pharma Solutions plans expansion in Scotland

In the first phase of the Grangemouth site expansion, two new ADC manufacturing suites, operational by Q3 2023, will be added to the existing three


Merck KGaA restructures life science business to support long-term growth
News | February 08, 2022

Merck KGaA restructures life science business to support long-term growth

Newly formed Life Science Services business unit to offer fully integrated CDMO and Contract Testing Services


Merck showcases potential for several cancers, MS and lupus
News | November 22, 2021

Merck showcases potential for several cancers, MS and lupus

Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline


Merck expands capacity for Antibody Drug Conjugate (ADC), therapies
Biotech | October 29, 2021

Merck expands capacity for Antibody Drug Conjugate (ADC), therapies

Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges


PharmaZell and Novasep come together to form a formidable API and CDMO platform
Biotech | September 17, 2021

PharmaZell and Novasep come together to form a formidable API and CDMO platform

They enter into exclusive negotiations in a new drive to create a technology-driven leader for complex small molecules and ADCs of global scale


Lonza extends collaboration with Biopharma company
News | July 19, 2021

Lonza extends collaboration with Biopharma company

As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies